TWO EDUCATIONAL SYMPOSIA





PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING, AVAILABLE VIA THE QR CODES BELOW, OR FROM VERTEX PHARMACEUTICALS AUSTRALIA: PHONE: 1800 179 987, EMAIL: vertexmedicalinfo@vrtx.com

PBS Information:

TRIKAFTA® is listed on the PBS for certain indications. Refer to the PBS Schedule for further details.

This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.



Abbreviations: CF: cystic fibrosis, UNC: University of North Carolina Vertex Pharmaceuticals (Australia) Pty. Ltd. Suite 3, Level 3, 601 Pacific Highway, St Leonards NSW 2065 Australia. Vertex Medical Information contact: 1 800 179 987 or email: vertexmedicalinfo@vrtx.com For details on the privacy policy of Vertex Pharmaceuticals, please visit www.vrtx.com/international-privacy

TRIKAFTA® is manufactured for Vertex Pharmaceuticals Incorporated. Vertex®, and the Vertex® logo, TRIKAFTA®, and the TRIKAFTA® logo, are registered trademarks of Vertex Pharmaceuticals Incorporated. © 2024 Vertex Pharmaceuticals Incorporated. AU-28-2400029. VETR33046W. July 2024.



Vertex invites you to:

A presentation on the US Experience of Treating Preschool Children* with TRIKAFTA®

And a case study discussion on **Evolving Challenges in CF**

International speaker A/Prof. Jennifer Goralski University of North Carolina at Chapel Hill, NC, USA



*Aged 2-5 years



(elexacaftor/tezacaftor/ivacaftor and ivacaftor)



2

С

LUNCH SYMPOSIUM

Friday 2 August 2024

US Experience of Treating Preschool Children with TRIKAFTA

International speaker

A/Prof. Jennifer Goralski University of North Carolina at Chapel Hill, NC, USA

Friday 2 August 2024

1:15 - 2:15 pm

Room P11, Plaza Level, Brisbane Convention & Exhibition Centre

Chair **Prof. Philip Robinson** The Poyal Children's Hospital Mellor

The Royal Children's Hospital, Melbourne, VIC

A/Prof. Jennifer Goralski

Jennifer Goralski, MD is an Associate Professor of Medicine and Paediatrics at the University of North Carolina at Chapel Hill, North Carolina, USA. A/Prof. Goralski provides clinical care to CF patients of all ages and serves as Co-Director of the UNC Adult Cystic Fibrosis Clinic.

She is heavily involved in CF research and has sustained research funding from the National Institue of Health as well as the CF Foundation. She has authored over 30 manuscripts in the field of CF and conducts multicentre clinical research in CF through the Therapeutics Development Network branch of the CF Foundation. She was a lead investigator on the VX20-445-111 trial of safety and tolerability of TRIKAFTA in preschool children ages 2–5 and was the first author on the subsequent publication in the American Journal of Respiratory and Critical Care Medicine.

A/Prof. Goralski currently serves as the US national principal investigator for the VX22-445-112 study, evaluating the long-term safety and efficacy of TRIKAFTA in CF participants aged 2 years and older.

BREAKFAST SYMPOSIUM

Saturday 3 August 2024

Evolving Challenges in CF: A Case Study Discussion

• Liver function • Carer treatment concerns • Mental health



Saturday 3 August 2024

7:15 – 8:15 am

Room P11, Plaza Level, Brisbane Convention & Exhibition Centre

Chair Dr. Juda

Dr Jude Morton Royal Adelaide Hospital, SA

Speakers

Dr Mark O'Carroll Auckland City Hospital, NZ



A/Prof. Jennifer Goralski University of North Carolina at Chapel Hill, NC, USA

Dr Jude Morton Royal Adelaide Hospital, SA

Meet the Expert at the Vertex Stand

Engage in discussion with A/Prof. Jennifer Goralski

Friday 2 August 2024 11:25 - 11:50 am (morning tea) 3:35 - 4:00 pm (afternoon tea)

Contact your Vertex representative for more information

Quan Luu

Key Account Manager M: 0499 533 667 E: quan_luu@vrtx.com **Grant Hayden**

Key Account Manager M: 0407 506 303 E: grant_hayden@vrtx.com